Drug Trial Radar · NCT07286149
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Aug 17, 2029
Study completion Apr 13, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Conditions
- Lung Neoplasm Malignant
Interventions
MK-1084Drug
Oral administration
Patritumab deruxtecanBiological
IV infusion
Sacituzumab tirumotecanBiological
IV Infusion
CetuximabBiological
IV Infusion
Rescue MedicationsDrug
Participants receive rescue medication at the investigator's discretion for prevention of nausea and vomiting, per approved product label. Recommended rescue medications are histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent), 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist, neurokinin 1 (NK-1) receptor antagonist and corticosteroid.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose Limiting Toxicity (DLT)Time frame: Up to 42 days
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 63 months
- Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 62 months
- Objective Response Rate (ORR)Time frame: Up to approximately 63 months
Locations
29 sites in 11 countries. Site status is shown where the registry gives one.
Clermont Oncology Center ( Site 0041)
Clermont, Florida · Recruiting
University of Illinois Hospital & Health Sciences System ( Site 0044)
Chicago, Illinois · Recruiting
Providence Portland Medical Center ( Site 0043)
Portland, Oregon · Recruiting
Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)
Portland, Oregon · Recruiting
Hospital São Lucas da PUCRS ( Site 0283)
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)
Barretos, São Paulo, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)
São José do Rio Preto, São Paulo, Brazil · Recruiting
Hospital Paulistano ( Site 0280)
São Paulo, São Paulo, Brazil · Recruiting
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)
Santiago, Region M. de Santiago, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0161)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0160)
Santiago, Region M. de Santiago, Chile · Recruiting
Guangdong Provincial People s Hospital ( Site 0300)
Guangzhou, Guangdong, China · Recruiting
Yunnan Province Cancer Hospital ( Site 0302)
Kunming, Yunnan, China · Recruiting
UniversitaetsklInikum Tuebingen ( Site 0192)
Tübingen, Baden-Wurttemberg, Germany · Recruiting
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)
Athens, Attica, Greece · Recruiting
Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)
Athens, Attica, Greece · Recruiting
Papageorgiou General Hospital of Thessaloniki ( Site 0206)
N.Efkarpia, Thessaloniki, Greece · Recruiting
Queen Mary Hospital ( Site 0230)
Hong Kong, Hong Kong · Recruiting
Hong Kong United Oncology Centre ( Site 0232)
Jordan, Hong Kong · Recruiting
Prince of Wales Hospital ( Site 0231)
Shatin, Hong Kong · Recruiting
Shaare Zedek Medical Center ( Site 0186)
Jerusalem, Israel · Recruiting
Meir Medical Center ( Site 0181)
Kfar Saba, Israel · Recruiting
Sheba Medical Center ( Site 0180)
Ramat Gan, Israel · Recruiting
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)
Meldola, Forli-Cesena, Italy · Recruiting
Severance Hospital, Yonsei University Health System ( Site 0080)
Seoul, South Korea · Recruiting
Hospital Clinic de Barcelona ( Site 0092)
Barcelona, Spain · Recruiting
Hospital Universitario Virgen Macarena ( Site 0093)
Seville, Spain · Recruiting
Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
Hospitalet, Barcelona, Spain · Recruiting
HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 0091)
Pozuelo de Alarcón, Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.